XR Pharmaceuticals Ltd is a startup established in 2018 to commercialise the drug design algorithm, which had been in development since 2010.
We are based in Cambridge, New Zealand.

Dr. Anatoly Chernyshev is the director and the algorithm developer. He holds PhD in Physical Chemistry, MSc in Organic Chemistry, and has several years of postdoctoral experience in Biophysical Chemistry.

Anatoly has been a recipient of several awards for innovative solutions in different areas of chemistry from InnoCentive and IdeaConnection companies. These include biomedical problems such as research and development of a biomarker for amyotrophic lateral sclerosis (ALS); identification of new promising protein targets for herbicides; controlling vertebrate pests in New Zealand. In computational chemistry Anatoly has developed an award winning algorithm to calculate birefringence in liquid crystals.

Special area of Anatoly’s interests is orphan diseases, in particular those linked to neurochemistry. Therefore the development of drugs for these conditions will receive the highest priority at XR Pharmaceuticals.

Publications

Kueffner R. et al. Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach. Nature Scientific Reports 9, Article number: 690 (2019) DOI:10.1038/s41598-018-36873-4